Periconception Antiretroviral Regimens Seem Safe in Women at Risk for HIV Acquisition

Preexposure prophylaxis (PrEP) with oral tenofovir or oral emtricitabine/tenofovir lowers risk for HIV infection in at-risk women. To assess the safety of these regimens in pregnant women, investigators analyzed data from 431 pregnancies in HIV-negative women who became pregnant while participating in a clinical trial of PrEP in HIV-discordant couples in Kenya and Uganda. The PrEP regimen was discontinued at the first monthly visit in which a positive pregnancy test occurred.

Incidence of pregnancy (overall, 10.3 per 100 person-years), preterm birth, and congenital anomalies as well as growth during the first year of life did not differ significantly between groups. Pregnancy loss occurred in 42.5% of women receiving emtricitabine/tenofovir …